Teplizumab
Teplizumab is a humanized anti-CD3 monoclonal antibody that binds to the CD3 epsilon chain of the T-cell receptor complex, inducing partial agonism and selectively modulating autoreactive T cells responsible for pancreatic beta-cell destruction in type 1 diabetes. It is approved to delay the onset of stage 3 type 1 diabetes in at-risk individuals aged 8 years and older, representing the first disease-modifying therapy for type 1 diabetes prevention. By shifting the balance from effector to regulatory T cells, it preserves residual beta-cell function.
Aires thérapeutiques
Mécanisme d'action
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Teplizumab is a humanized anti-CD3 monoclonal antibody that binds to the CD3 epsilon chain of the T-cell receptor complex, inducing partial agonism and selectively modulating autoreactive T cells responsible for pancreatic beta-cell destruction in type 1 diabetes. It is approved to delay the onset of stage 3 type 1 diabetes in at-risk individuals aged 8 years and older, representing the first disease-modifying therapy for type 1 diabetes prevention. By shifting the balance from effector to regulatory T cells, it preserves …
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Teplizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743078. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="teplizumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/teplizumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/teplizumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/teplizumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="teplizumab"></drugfyi-drug>